MeSH term
Frequency | Condition_Probility | Female | 5 | 0.0 |
Genes, abl/*genetics | 6 | 35.0 |
Genetic Heterogeneity | 2 | 0.0 |
Humans | 24 | 0.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Karyotyping | 2 | 0.0 |
Leukemia, Myeloid, Chronic/*genetics | 2 | 3.0 |
Male | 9 | 0.0 |
Research Support, Non-U.S. Gov't | 21 | 0.0 |
Translocation, Genetic/genetics | 2 | 2.0 |
Amino Acid Sequence | 2 | 0.0 |
Base Sequence | 2 | 0.0 |
Chromosomes, Human, Pair 9/genetics | 2 | 1.0 |
Enzyme Inhibitors/therapeutic use | 2 | 2.0 |
*Genes, abl | 3 | 10.0 |
Molecular Sequence Data | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 6 | 0.0 |
Adolescent | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Fusion Proteins, bcr-abl/*genetics | 3 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 6 | 0.0 |
Comparative Study | 3 | 0.0 |
Adult | 5 | 0.0 |
*DNA Methylation | 3 | 0.0 |
Middle Aged | 4 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Chromosome Deletion | 3 | 0.0 |
Oncogene Proteins, Fusion/*genetics | 2 | 1.0 |
Bladder Neoplasms/*genetics | 2 | 2.0 |
Carcinoma, Transitional Cell/*genetics | 2 | 6.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Leukemia, Myeloid, Chronic/*genetics/pathology | 2 | 12.0 |
Philadelphia Chromosome | 2 | 4.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Animals | 3 | 0.0 |
Mice | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Piperazines/*therapeutic use | 2 | 4.0 |
Pyrimidines/*therapeutic use | 2 | 4.0 |
*Chromosomes, Human, Pair 9 | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
In Vitro | 2 | 0.0 |
In Situ Hybridization, Fluorescence/methods | 2 | 2.0 |
Chromosome Aberrations | 2 | 0.0 |
Gene Amplification/genetics | 2 | 3.0 |
